Pharmaprom Invests 75 Million Dirhams in Casablanca Facility Expansion

Pharmaceutical manufacturer Pharmaprom is set to invest 75 million dirhams in expanding its production facility in Lissasfa near Casablanca,signaling growing confidence in Morocco’s pharmaceutical sector. The expansion,led by CEO Naoual Benyezzar,aims to significantly increase the company’s industrial and logistics capabilities as it targets 150 million dirhams in revenue within three years.

The investment comes three years after business magnates Mohamed Bouzoubaa and Mohamed Saad Berrada,through their vehicles BFO Partners and BMPAR,acquired control of the laboratory from founder Fouad Bouchta in 2022. The new owners,known for their success in confectionery and real estate respectively,are accelerating growth in a pharmaceutical market that continues expanding despite periodic government-mandated price reductions.

Morocco’s pharmaceutical market is projected to grow at a compound annual rate of 4.67% through 2029,reaching a market volume of $829.30 million. This growth trajectory reflects increasing government healthcare investments,rising health consciousness among consumers,and growing demand for both over-the-counter and generic medications.

Pharmaprom specializes in manufacturing pharmaceutical products for challenging therapeutic areas,including oncology,gynecology,antibiotics,and contrast agents. The company has positioned itself as a key supplier for serious pathologies in the Moroccan market,focusing on addressing unmet medical needs through partnerships with qualified international laboratories.

The expansion aligns with broader sector trends as Morocco strengthens its position as Africa’s second-largest pharmaceutical manufacturer by volume. Recent industry developments include strategic partnerships between local firms and international players,with companies like Cooper Pharma collaborating with China’s Jemincare and Hikma Pharmaceuticals preparing to launch new sterile injectable facilities.

The pharmaceutical sector’s resilience was demonstrated during the COVID-19 pandemic when local manufacturers successfully maintained supply chains without experiencing shortages. This reliability,combined with Morocco’s WHO “Europe” zone classification and compliance with FDA and European standards,continues attracting investment from multinational pharmaceutical companies seeking North African production bases.